03.

Investors

NextCell is listed on Nasdaq First North Growth Market. The drug candidate ProTrans is a platform technology aimed at developing cell therapies to treat autoimmune diseases and other inflammatory conditions.
The company's primary indication is type 1 diabetes, where both safety and effectiveness concerning the preservation of patients' ability to produce their own insulin have been demonstrated in clinical drug trials with their drug candidate, ProTrans. The company's other business area, Cellaviva, represents Scandinavia's largest family preservation of stem cells.

Here, you can find the financial calendar, reports, stock information, and corporate governance details.

IR-contact: Patrik Fagerholm, 073-073 14 76, patrik.fagerholm@nextcellpharma.com

Financial calendar

Q1 report 2023
January 26, 2023
Q2 report 2023
April 27, 2023
Q3 report 2023
July 27, 2023
Year End Report 2023
October 26, 2023
Annual General Meeting
November 30, 2023

Financial reports

2028

No reports published yet.

2027

No reports published yet.

2026

No reports published yet.

2025

No reports published yet.

2024

No reports published yet.

Corporate Governance

Auditor

Öhrlings PricewaterhouseCoopers AB (PwC)
Torsgatan 21, 113 97 Stockholm

PwC has been the company's auditor since 2014. The primary auditor, since 2018, is Johan Engstam. Johan Engstam is an Authorized Public Accountant and a member of FAR, the institute for the accountancy profession in Sweden.

Articles Of Association

Download

Certified Adviser

FNCA Sweden AB

Address: Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm

Phone: +46(0)8-528 00 399

Mail: info@fnca.se

The Share

Shareholders

List of 10 largest shareholders as of June 30, 2023:

‍‍

Owner
Shares
Percentage
Diamyd Medical AB
4,283,861
12.5
Försäkringsbolaget Avanza Pension
3,513,301
10.2
Anders Essen-Möller*
2,558,005
7.5
Ålandsbanken i ägares ställe
1,223,243
3.6
Pabros AB
847,452
2.5
Christer Janssson
822,623
2.4
Nordnet Pensionsförsäkring AB
651,755
1.9
Konstruktions och Försäljningsaktiebolaget KFAB
650,000
1.9
Nordea LIvförsäkring Sverige AB
588,513
1.7
Filip Wirefors
512,000
1.5
Total
15,650,753
45.5
* In addition to Chairman of the Board, Anders Essen-Möller's directly registered holdings, this item includes holdings of 4.09 percent managed by Avanza Pension.

Trading information

NextCell Pharma AB is listed on the Nasdaq First North Growth Market since July 2020. The stock is traded under the ticker “NXTCL”. ISIN Code: SE0009723125.

The current share price is available on Nasdaq First North website:

Nasdaq OMX Nordic

Dividend policy

NextCell has to date paid no dividends to its shareholders. The company is in a development phase, and any surplus is primarily planned for reinvestment in the company’s development.

Subscribe to press releases

By filling out the form you are approving that NextCell Pharma stores your information. Read more about our integrity policy (in Swedish) here.
I am not a robot.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form. Please try again.

Archived documents